Downloading...
Download

VCEL

Vericel (VCEL) AnalysisCompany Overview: Vericel is a biopharmaceutical company specializing in cellular treatments for severe burn care and sports medicine. The company's flagship product, MACI, is used for knee cartilage replacement and has been a significant growth driver, achieving a 22% revenue increase along with record numbers of implants, biopsies, and surgeon usage. Product Pipeline: Vericel is poised to launch two potential blockbuster drugs: Epicel: A skin graft for severe burns, which also experienced a 22% revenue growth. Nexobrid: An ointment for removing dead burned skin to improve healing, became available in Q4. Investment Outlook: Bullish Outlook: We are bullish on NASDAQ:VCEL above the $43.00-$44.00 range. Upside Potential: With an upside target set at $64.00-$65.00, investors should consider Vericel's strong product performance and promising pipeline as key drivers for potential stock appreciation. 📈🔍 Monitor Vericel for promising investment opportunities! #VCEL #Biopharmaceuticals 💉🏥
NASDAQ:VCELLong
by Richtv_official
And Vericel Too. VCEL are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
NASDAQ:VCELLong
by Rykin_Capital
Another biotech that looks promising: VCELTaking small long position. Will add if break up and close above horizontal resistance line and the long term down trend line. My personal stop is a close < 5.45 (dashed horizontal line on the daily). Process your way. Company business: Vericel Corp. engages in the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two cell therapy products in the United States of America, Carticel autologous cultured chondrocytes, an autologous chondrocyte implant for the treatment of cartilage defects in the knee and Epicel cultured epidermal autografts, a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
NASDAQ:VCELLong
by goodguy
Breaking 3$ and we could runChart looking ready. Fidelity equity summery score 9.1 up from 8.3 yesterday. Login to see. eresearch.fidelity.com VCEL new article: Vericel Corp (NASDAQ:VCEL)’s PDUFA Is Drawing Near streetregister.com also: VCEL Vericel to Present at 2016 Cell & Gene Meeting on the Mesa on Wednesday, October 5, 2016 at 5:45pm Pacific time. finance.yahoo.com also reminder: VCEL - November 14 (Monday) please also mark your calendar: Vericel to Present Data at the American Heart Association's Scientific Sessions 2016 on the Reduction of Ventricular Arrhythmias with Ixmyelocel-T in the ixCELL-DCM Clinical Trial investors.vcel.com
NASDAQ:VCELLong
by thegoldenbags